StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $43.23 | $42.54 | -1.61% | 2.4M |
| 05-13 | $42.47 | $42.65 | +0.42% | 1.8M |
| 05-14 | $42.45 | $40.79 | -3.91% | 1.5M |
| 05-15 | $40.35 | $39.50 | -2.11% | 1.7M |
| 05-18 | $39.94 | $39.48 | -1.15% | 1.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $204.92M | $616.29M | $423.71M | $262.00M |
Operating Income | $34.80M | $123.32M | $72.83M | $43.47M |
Net Income | $19.78M | $447.18M | $424.14M | $28.19M |
EPS (Diluted) | $0.12 | $2.77 | $2.62 | $0.20 |
Total Assets | $1.53B | $1.06B | $1.03B | $702.61M |
Total Liabilities | $945.71M | $415.23M | $417.81M | $426.18M |
Cash & Equivalents | $442.21M | $79.15M | $74.08M | $129.13M |
Free Cash Flow OCF − CapEx | $-17.95M | $-24.99M | $-44.58M | $-21.35M |
Shares Outstanding | 153.09M | 155.31M | 155.21M | 158.03M |